Abstract
Purpose Homocysteine is associated with cardiovascular, inflammation and autoimmune diseases.
Previous studies have shown that thyroid peroxidase antibody is associated with homocysteine
levels in hypothyroidism. The relationship between thyroid antibodies and homocysteine
in hyperthyroidism remains unclear. In this study, we aimed to investigate the association
of thyroid antibodies with homocysteine in patients with Graves’ disease.
Methods This was a cross-sectional study including 478 Graves’ disease patients who were
consecutively admitted and underwent radioiodine therapy. Homocysteine, thyroid hormones,
thyroid antibodies, glucose and lipids were measured.
Results Patients with homocysteine levels above the median were older and had unfavorable
metabolic parameters compared to patients with homocysteine levels below the median.
Thyroglobulin antibody or thyroid peroxidase antibody was associated with homocysteine
levels (β=0.56, 95%CI 0.03-1.08, p=0.04; β=0.75, 95%CI 0.23-1.27, p=0.005). The relationship
between thyroid peroxidase antibody and homocysteine remained significant when additionally
adjusting for free triiodothyronine (β=0.76, 95%CI 0.24-1.28, p=0.004). The presence
of a homocysteine level above the median increased significantly with increasing thyroid
peroxidase antibody quartiles in the logistic regression (OR=1.74, 95%CI 1.27-2.39,
P for trend=0.001). Homocysteine levels increased significantly with increasing thyroid
peroxidase antibody quartiles (p=0.005). Thyroid peroxidase antibody had no significant
effect on other traditional cardiovascular risk factors.
Conclusions Thyroid peroxidase antibody is independently and positively associated with homocysteine
levels in patients with Graves’ disease. Thyroid peroxidase antibody may be associated
with the cardiovascular risk of patients with Graves’ disease through its effect on
homocysteine.
Key words
human - cardiovascular risk - hyperthyroidism
